Chief Executive Officer
Michael Forer serves as Chief Executive Officer of ADC Therapeutics; he is also Partner, European Origination for Auven Therapeutics. Prior to joining ADC Therapeutics and Auven, Mr Forer co-founded Rosetta Capital Limited, a London-based advisory and private equity firm focused on the life science sector. Mr Forer was an active corporate finance and M&A advisor to international private equity backed clients.
Prior to this, Mr Forer was an investment manager at Rothschild Asset Management, responsible for origination, execution, and management of private equity investments in the life science sector. During his tenure, the team delivered more than $200 million in cash divestments, delivered fund returns in excess of 44% IRR, and the Rothschild portfolio grew to more than $1 billion in value.
While at a leading Canadian law firm, now Norton Rose, Mr Forer was called to the Bar for the Law Society of Upper Canada. He is also a former board member of Medical Devices Canada, a trade and lobby association. He is based at ADC Therapeutic’s headquarters in Switzerland.